Prognostic evaluation and staging optimization of the Mayo Additive Staging System (MASS) in real world for newly diagnosed multiple myeloma patients

Performance of newer myeloma staging systems in a contemporary, large patient cohort

“…Our work represents the first comparison of these newer staging systems to each other, and the first to externally validate both of them simultaneously in a large multi-center contemporary United States cohort treated with modern triplet therapy. Previous work has evaluated these staging systems in small single-center analyses, such as two single-center reports from China evaluating the performance of MASS in 94 [ 9 ] and 307 patients [ 10 ], respectively. Similar single-center studies have also evaluated the performance of R2-ISS in cohorts from China and Japan [ 11 , 12 ].…”